Pharmacokinetic profile of 3β-hydroxy-17-(1H-1,2,3-triazol-1-yl)androsta-5,16-diene (VN/87-1), a potent androgen synthesis inhibitor, in mice

Journal of Steroid Biochemistry and Molecular Biology

Volumn 78, Issue 3, 2001, Pages 241-246

  Nnane, I P ^a   Njar, V C O ^b   Brodie, Angela A ^b  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

17 hydroxylase C17,20 lyase; 17 azolyl steroid; Pharmacokinetics; Prostate cancer

Indexed keywords

3BETA HYDROXY 17 (1H 1,2,3 TRIAZOL 1 YL)ANDROSTA 5,16 DIENE; STEROID; UNCLASSIFIED DRUG; 3 HYDROXY 17 (1H 1,2,3 TRIAZOL 1 YL)ANDROSTA 5,16 DIENE; 3-HYDROXY-17-(1H-1,2,3-TRIAZOL-1-YL)ANDROSTA-5,16-DIENE; ANDROSTANE DERIVATIVE; ANTIANDROGEN; STEROID 17ALPHA MONOOXYGENASE; TRIAZOLE DERIVATIVE;

ANDROGEN SYNTHESIS; ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; GASTROINTESTINAL TRACT; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PROSTATE CANCER; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SCID MOUSE; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; BIOAVAILABILITY; CANCER TRANSPLANTATION; CELL CULTURE; DRUG ANTAGONISM; HUMAN; METABOLISM; MOUSE MUTANT; PROSTATE TUMOR; XENOGRAFT;

ANIMALIA;

ANDROGEN ANTAGONISTS; ANDROSTANOLS; ANIMALS; BIOLOGICAL AVAILABILITY; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, SCID; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS; STEROID 17-ALPHA-HYDROXYLASE; TRANSPLANTATION, HETEROLOGOUS; TRIAZOLES; TUMOR CELLS, CULTURED;

EID: 0034740808     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(01)00096-6     Document Type: Article

References (17)

1. Epidemiology of prostate cancer
2. Cancer statistics
3. Some aspects of relation of structure of steroids to their prostate stimulating effects
4. Three-month treatment of a long acting gonadotrophin-releasing hormone agonist of patients with benign prostatic hyperplasia: Effects of tissue adrogen concentration, 5a-reductase activity and androgen receptor content
5. Hormonal therapy for prostate cancer
6. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis
7. 17,20-lyase and 5α-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer
8. Testicular microsomal P-450 for C21 steroid side chain cleavage: Spectral and binding studies
9. 17): Potential agents for the treatment of prostate cancer
10. Optimal dosing of ketoconazole and hydrocortisone leads to long responses in hormone refractory prostate cancer
11. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal
12. Immediate hormonal therapy vs. observation for node positive prostate cancer following radical prostatectomy and pelvic lymphadenectomy: A randomised Phase III Eastern Cooperative oncology Group/Inter Group Trial
13. 17α): Potent inhibitors for the treatment of prostate cancer
14. Effects of novel 17-azolyl compounds on androgen synthesis in vitro and in vivo
15. 17,20-lyase inhibitors on LNCaP prostate cancer cell growth in vitro and in vivo
16. 17α)
17. Anti-tumour effects and pharmacokinetic profile of a novel inhibitor of androgen synthesis; the internal standard, 17-(5′-isoxazolyl)androsta-4,16-dien-3-one (L-39), in mice